•  
  •  
 

Subject Area

Internal Medicine

Article Type

Original Study

Abstract

Objective The aim of this study was to examine the efficacy of high-dose atorvastatin in preventing contrast-induced nephropathy (CIN) in statin-naive patients with moderate or high risk of CIN undergoing coronary angiography. Background CIN occurs in 20–30% of patients who receive standard preventive measures. This means that current treatments are not adequate. Patients and methods The present study included 300 patients scheduled for coronary angiography. They were randomized into two groups: the atorvastatin group received 80-mg atorvastatin 12 h before the procedure, with a further 40-mg preprocedural dose, and the placebo group did not receive the loading dose of atorvastatin. The primary end point of the study was evaluation of renal function before and 48 h after contrast-medium administration. Results A total of 300 patients were included in this study. The incidence of nephropathy in the placebo group was 20% (30 patients), whereas the incidence in the atorvastatin group was 9.3% (14 patients) (P = 0.009). Conclusion High-dose atorvastatin has a significant protective role against contrast-induced nephropathy in patients with moderate and high risk for contrast nephropathy undergoing coronary angiography.

Download

Share

COinS